drugset / Trial / NCT00135798

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

NCT00135798

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV and allograft hepatitis following liver transplant.

Timeline

Start
2005-09
Primary completion
2009-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2b Protein / enzyme biologic 1.5 ug/kg
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg